These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20182803)

  • 1. The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis.
    Yuan FL; Li X; Lu WG; Li CW; Li JP; Wang Y
    Mol Biol Rep; 2010 Oct; 37(7):3561-6. PubMed ID: 20182803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of the V-ATPase functionality as a way to uncouple bone formation and resorption - a novel target for treatment of osteoporosis.
    Thudium CS; Jensen VK; Karsdal MA; Henriksen K
    Curr Protein Pept Sci; 2012 Mar; 13(2):141-51. PubMed ID: 22044152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
    Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
    Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of osteoclast vacuolar H(+)-ATPase.
    Farina C; Gagliardi S
    Curr Pharm Des; 2002; 8(23):2033-48. PubMed ID: 12171517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. V-ATPases and osteoclasts: ambiguous future of V-ATPases inhibitors in osteoporosis.
    Duan X; Yang S; Zhang L; Yang T
    Theranostics; 2018; 8(19):5379-5399. PubMed ID: 30555553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.
    Xu J; Cheng T; Feng HT; Pavlos NJ; Zheng MH
    Histol Histopathol; 2007 Apr; 22(4):443-54. PubMed ID: 17290355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
    Sørensen MG; Henriksen K; Neutzsky-Wulff AV; Dziegiel MH; Karsdal MA
    J Bone Miner Res; 2007 Oct; 22(10):1640-8. PubMed ID: 17576165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
    Nyman JK; Väänänen HK
    Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
    Niikura K; Takano M; Sawada M
    Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel bone antiresorptive agents that selectively inhibit the osteoclast V-H+-ATPase.
    Farina C; Gagliardi S; Nadler G; Morvan M; Parini C; Belfiore P; Visentin L; Gowen M
    Farmaco; 2001; 56(1-2):113-6. PubMed ID: 11347950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational identification of enoxacin as a novel V-ATPase-directed osteoclast inhibitor.
    Toro EJ; Ostrov DA; Wronski TJ; Holliday LS
    Curr Protein Pept Sci; 2012 Mar; 13(2):180-91. PubMed ID: 22044158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of osteoclast bone resorption by disrupting vacuolar H+-ATPase a3-B2 subunit interaction.
    Kartner N; Yao Y; Li K; Crasto GJ; Datti A; Manolson MF
    J Biol Chem; 2010 Nov; 285(48):37476-90. PubMed ID: 20837476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iejimalides show anti-osteoclast activity via V-ATPase inhibition.
    Kazami S; Muroi M; Kawatani M; Kubota T; Usui T; Kobayashi J; Osada H
    Biosci Biotechnol Biochem; 2006 Jun; 70(6):1364-70. PubMed ID: 16794315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific biological functions of vacuolar-type H(+)-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts.
    Sahara T; Itoh K; Debari K; Sasaki T
    Anat Rec A Discov Mol Cell Evol Biol; 2003 Feb; 270(2):152-61. PubMed ID: 12524690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoplasmic terminus of vacuolar type proton pump accessory subunit Ac45 is required for proper interaction with V(0) domain subunits and efficient osteoclastic bone resorption.
    Feng H; Cheng T; Pavlos NJ; Yip KH; Carrello A; Seeber R; Eidne K; Zheng MH; Xu J
    J Biol Chem; 2008 May; 283(19):13194-204. PubMed ID: 18227071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption.
    Wu H; Xu G; Li YP
    J Bone Miner Res; 2009 May; 24(5):871-85. PubMed ID: 19113919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the osteoclast V-ATPase by small interfering RNAs.
    Hu Y; Nyman J; Muhonen P; Väänänen HK; Laitala-Leinonen T
    FEBS Lett; 2005 Sep; 579(22):4937-42. PubMed ID: 16115623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
    Niikura K; Takeshita N; Takano M
    J Bone Miner Res; 2005 Sep; 20(9):1579-88. PubMed ID: 16059630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity.
    Gagliardi S; Nadler G; Consolandi E; Parini C; Morvan M; Legave MN; Belfiore P; Zocchetti A; Clarke GD; James I; Nambi P; Gowen M; Farina C
    J Med Chem; 1998 May; 41(10):1568-73. PubMed ID: 9572882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific inhibitors of vacuolar H(+)-ATPase trigger apoptotic cell death of osteoclasts.
    Okahashi N; Nakamura I; Jimi E; Koide M; Suda T; Nishihara T
    J Bone Miner Res; 1997 Jul; 12(7):1116-23. PubMed ID: 9200012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.